CREATE Medicines Unveils All-RNA T-Cell Engineering Platform RetroT for In Vivo CAR Therapy
核心洞察
CREATE Medicines (搜索) announced preclinical data for RetroT (搜索), a fully RNA-encoded gene-integration system that enables site-specific CAR insertion into T cells without double-strand DNA breaks or viral vectors.
The platform successfully integrated CD19-CAR (搜索) transgenes into human T cells using LINE-1 (搜索) retrotransposon machinery, demonstrating full functionality and target-specific cytotoxicity with no detectable off-target effects.
RetroT (搜索) represents a potential breakthrough in precision gene editing by reducing genotoxicity associated with traditional CRISPR/Cas9 methods while maintaining the flexibility for repeat dosing.
CREATE Medicines (搜索) has unveiled preclinical data for RetroT (搜索), a groundbreaking all-RNA T-cell engineering platform that enables site-specific, durable CAR integration directly within the body. The results, presented at the Cold Spring Harbor Laboratory Meeting on Immune Engineering & Cellular Immunotherapy, demonstrate successful genetic delivery of CAR constructs to T cells without the safety concerns associated with traditional gene editing approaches.
Revolutionary RNA-Based Gene Integration
RetroT (搜索) utilizes human LINE-1 (搜索) retrotransposon machinery to drive programmable, site-specific integration of multi-kilobase payloads without creating double-strand DNA breaks (DSBs). This approach supports a superior genomic safety profile compared to conventional CRISPR/Cas9 methods, which are associated with off-target effects and genotoxicity.
"RetroT (搜索) reframes what's possible, a purely RNA-based system that programs T cells in vivo with site-specific, durable gene insertion while maintaining the flexibility to re-dose," said Robert Hofmeister, PhD, Chief Scientific Officer of CREATE Medicines (搜索). "When combined with our targeted LNP delivery and human-validated mRNA platform, RetroT provides a direct and scalable path to clinical proof of concept."
Successful CD19-CAR Integration Demonstrates Platform Potential
In the presented study, CREATE Medicines (搜索) successfully used RetroT (搜索) to insert a CD19-CAR (搜索) transgene into human T cells. The platform harnesses the natural mobility of the LINE-1 (搜索) retrotransposon, described as the only active "jumping gene" in the human genome, combined with a CRISPR-based nickase to achieve precise genetic integration.
The engineered T cells demonstrated full functionality and target-specific cytotoxicity while preserving cell fitness and phenotype. Critically, sequencing analysis confirmed precise integration with no detectable off-target effects, partial insertions, or genomic scars, addressing key safety concerns that have limited traditional gene editing approaches.
Advancing In Vivo CAR Therapy Development
RetroT (搜索) integrates genetic payloads without requiring viral vectors or DNA templates, potentially transforming precision in vivo gene editing. The platform's ability to reduce off-target effects while maintaining therapeutic efficacy positions it as a significant advancement in the CAR-T therapy field.
CREATE Medicines (搜索) continues to advance its multi-immune programming platform, which enables selective programming of T cells, myeloid cells, and NK cells directly within the body. The company's pipeline includes next-generation in vivo CAR therapies targeting solid tumors (搜索) and autoimmune diseases (搜索), supported by a validated lipid nanoparticle (LNP) delivery platform and proprietary RNA engineering technology.
The RetroT (搜索) platform builds on research published in EMBO Reports, titled "CRISPR-Enabled Autonomous Transposable Element (CREATE) for RNA-based gene editing and delivery" (Wang et al., EMBO Rep (2025)26:1062–1083), providing additional scientific validation for the approach.
CREATE Medicines (搜索), formerly known as Myeloid Therapeutics, describes itself as a clinical-stage biotechnology company pioneering in vivo multi-immune programming. The company's proprietary mRNA-LNP platform directly programs immune cells inside the body to deliver scalable, repeat-dose, off-the-shelf immunotherapies with proven human validation and next-generation RNA technology.